v3.25.2
Revenue from Contracts with Customers (Tables)
6 Months Ended
Jun. 30, 2025
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue

The following tables present revenue from contracts with customers by reporting segment, product category and geographic region for the three and six-month periods ended June 30, 2025 and 2024 (in thousands):

Three Months Ended

Three Months Ended

June 30, 2025

June 30, 2024*

    

United States

    

International

    

Total

    

United States

    

International

    

Total

Cardiovascular

 

  

 

 

  

 

  

 

  

 

  

Peripheral Intervention

$

83,987

$

58,860

$

142,847

$

77,627

$

56,759

$

134,386

Cardiac Intervention

 

46,100

69,151

 

115,251

 

36,830

56,477

 

93,307

Custom Procedural Solutions

 

32,710

20,924

 

53,634

 

30,454

19,678

 

50,132

OEM

 

46,932

5,361

 

52,293

 

40,241

9,749

 

49,990

Total

 

209,729

154,296

 

364,025

 

185,152

 

142,663

 

327,815

 

Endoscopy

Endoscopy Devices

 

17,353

 

1,084

 

18,437

 

9,512

 

676

 

10,188

Total

$

227,082

$

155,380

$

382,462

$

194,664

$

143,339

$

338,003

Six Months Ended

Six Months Ended

June 30, 2025

June 30, 2024*

   

United States

   

International

   

Total

   

United States

   

International

   

Total

Cardiovascular

 

 

 

  

 

  

 

  

 

  

Peripheral Intervention

$

164,144

$

115,982

$

280,126

$

152,431

$

112,021

$

264,452

Cardiac Intervention

 

87,499

127,493

 

214,992

 

72,167

111,316

 

183,483

Custom Procedural Solutions

 

61,938

39,638

 

101,576

 

59,708

38,947

 

98,655

OEM

 

93,960

12,084

 

106,044

 

77,391

17,208

 

94,599

Total

 

407,541

295,197

 

702,738

 

361,697

 

279,492

 

641,189

 

Endoscopy

Endoscopy Devices

 

33,105

 

1,970

 

35,075

 

19,061

 

1,261

 

20,322

Total

$

440,646

$

297,167

$

737,813

$

380,758

$

280,753

$

661,511

*Commencing January 1, 2025, we reorganized our sales teams and product categories to include revenues from the sale of our spine devices under our OEM product category. Revenue figures for 2024 have been recast to reflect this realignment of our portfolio of spine products, representing approximately $5.7 million and $11.0 million in revenue for the three and six-month periods ended June 30, 2024, within the OEM product category to provide comparability between the reported periods.